Univariate Univariate Univariate Multivariate Multivariate Multivariate
variable No CAE(n=78) CAE(n=18) HR 95%CI P HR 95%CI P
Baseline characteristics Baseline characteristics Baseline characteristics Baseline characteristics Baseline characteristics Baseline characteristics
Age(y) 49.7±11.8 49.4±11.3 1.011 0.971-1.052 0.6
Men 57(60%) 45(58%) 1.489 0.558-3.977 0.427
Weight(kg) 65±9.8 64±10 1.003 0.958-1.051 0.89
Follow-up period(d) 2242±281 2248±280 0.999 0.997-1.001 0.223
Cumulative dose of doxorubin (mg/m2) 379.9±94.0 378.7±94.7 1.001 0.996-1.005 0.81
Cardiac risk factors
BP>140/90mm Hg 15(16%) 12(15%) 1.198 0.347-4.141 0.775
Diabetes mellitus 6(6%) 4(5%) 2.144 0.493-9.336 0.309
Smoking 29(30%) 23(29%) 1.373 0.512-3.687 0.529
3D Echocardiography after the 3D Echocardiography after the 3D Echocardiography after the 3D Echocardiography after the 3D Echocardiography after the 3D Echocardiography after the
completion chemotherapy completion chemotherapy completion chemotherapy completion chemotherapy completion chemotherapy completion chemotherapy
Left ventricular parameters
LVEF(%) 57.0±5.2 54.3±7.7 0.918 0.841-1.002 0.055
LVEDV 73.9±13.3 76.7±15.3 1.014 0.981-1.048 0.414
LVESV 31.8±7.2 35.4±11.0 1.051 0.995-1.110 0.077
LVGLS 20.1±3.2 16.7±3.3 0.743 0.633-0.873 <.001* 0.774 0.628-0.953 .016+
LVGCS 26.3±4.0 24.1±4.7 0.88 0.779-0.994 .040* 1.02 0.869-1.197 0.812
Right ventricular parameters
RVEF(%) 49.2±4.4 44.3±4.4 0.848 0.785-0.916 <.001* 0.895 0.821-0.976 .012+
RVEDV 66.6±13.6 68.0±16.0 1.01 0.976-1.044 0.578
RVESV 33.9±8.0 38.5±9.4 1.06 1.009-1.112 .019* 1..044 0.982-1.111 0.167
RVLFS 15.9±6.4 18.3±9.2 0.955 0.883-1.034 0.255
RVLSS 24.4±5.3 22.6±8.9 1.046 0.982-1.114 0.159